Tanya Bowsher
Family · Bourbonnais, ILNPI 1952799843
Payments from drug & device makers
Across 78 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$233
- Lilly USA, LLC$170
- Daiichi Sankyo Inc.$144
- Jazz Pharmaceuticals Inc.$135
- Merck$114
- Pfizer$99
- plus $936 from 27 others
What the payments were for
- Food & beverage$1,52683%
- Education$30517%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $233 |
| Lilly USA, LLC | 3 | $170 |
| Daiichi Sankyo Inc. | 7 | $144 |
| Jazz Pharmaceuticals Inc. | 5 | $135 |
| Merck | 6 | $114 |
| Pfizer | 5 | $99 |
| Sanofi-aventis U.S. LLC | 1 | $96 |
| Incyte Corporation | 4 | $74 |
| Bayer | 3 | $67 |
| Novartis | 3 | $63 |
| Bristol Myers Squibb | 2 | $59 |
| Johnson & Johnson | 3 | $56 |
| Tersera Therapeutics LLC | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Eisai Inc. | 3 | $46 |
| Array Biopharma Inc | 1 | $30 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Sanofi | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Genmab U.S., Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Rigel Pharmaceuticals, Inc. | 1 | $21 |
| Taiho Oncology, Inc. | 1 | $19 |
| Beone Medicines USA, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Exelixis Inc. | 1 | $17 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Abbott | 1 | $14 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERZENIO$109
How this compares
$1,832 in reported general payments places this provider in the 80th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Chloride | 12 | $195 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $128 |
| Glipizide | 11 | $51 |
| Lisinopril | 13 | $43 |
Paid to pharmacies, not to this prescriber.
Other family in Bourbonnais
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.